Mycophenolate Mofetil Teva (Mycophenolate Mofetil)

The drug is a pro‑drug that is converted to mycophenolic acid, which inhibits the enzyme inosine monophosphate dehydrogenase. This blocks the synthesis of guanosine nucleotides needed for lymphocyte proliferation, thereby reducing the activity of T‑ and B‑cells that drive immune responses.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s transplant type, renal function, and overall health. Dosage may be adjusted over time, and patients should follow the prescriber’s instructions without deviation.

Mycophenolate Mofetil is classified as Pregnancy Category X because it can cause fetal malformations and pregnancy loss. It is contraindicated in pregnant women and should be discontinued before conception. Breastfeeding is not recommended as the drug is excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, Mycophenolate Mofetil offers a different mechanism—targeting nucleotide synthesis rather than calcium signaling. It is often used in combination regimens to provide synergistic immunosuppression while allowing lower doses of each agent, potentially reducing individual drug toxicity.

The product should be stored at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, heat, and direct sunlight. Do not refrigerate or freeze unless the packaging specifically indicates otherwise.

Mycophenolate Mofetil Teva is taken orally, usually with food or a glass of water to lessen gastrointestinal irritation. The tablets are swallowed whole and should not be crushed or chewed unless directed by a healthcare professional.

Serious risks include bone‑marrow suppression leading to low blood counts, severe infections due to immunosuppression, liver toxicity, and teratogenic effects that can cause birth defects. Patients should be monitored regularly for these complications and report any concerning symptoms promptly.

The drug is contraindicated in pregnant women, individuals with known hypersensitivity to mycophenolate or its components, and patients with severe uncontrolled infections. Caution is also advised for those with significant renal or hepatic impairment, and live vaccines should be avoided.